GlassScriptPhysician profile
Leslie E Schwartz
NPI 1013337369
$2,396.93
in general payments reported to CMS, 2019-2025
30 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $705 · 2021: $577 · 2022: $13.53 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.00 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.33 | 2019-2021 | |
| Novo Nordisk INC | $179.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $177.99 | 2019-2025 | Shingrix |
| Amgen INC. | $131.34 | 2019-2021 | |
| Pfizer INC. | $116.95 | 2019-2020 | |
| Intuitive Surgical, INC. | $105.69 | 2025 | |
| Nestle Healthcare Nutrition INC. | $88.82 | 2020-2021 | |
| Astellas Pharma US INC | $88.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $87.28 | 2019-2021 | |
| Janssen Biotech, INC. | $81.19 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.07 | 2019-2020 | |
| Lilly USA, LLC | $66.84 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.16 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $42.08 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.20 | 2019-2020 | |
| Romark Laboratories, Lc | $27.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.71 | 2021 | |
| Coastal Medical Technologies LLC | $27.67 | 2025 | |
| Allergan, INC. | $25.57 | 2019-2020 | |
| Therapeuticsmd, INC. | $25.42 | 2019 | |
| Intercept Pharmaceuticals, INC. | $24.65 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.62 | 2021 | |
| Genentech USA, INC. | $18.07 | 2021 | |
| Daiichi Sankyo INC. | $17.71 | 2019 | |
| Abbott Laboratories | $15.55 | 2020 | |
| Alfasigma USA, INC. | $14.66 | 2020 | |
| Redhill Biopharma INC. | $14.41 | 2021 | |
| Shire North American Group INC | $11.84 | 2019 | |
| Merck Sharp & Dohme LLC | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.